glp-1 agonists and sglt2 inhibitors Receptor in Diabetic Kidney Disease: Evolving Evidence and Clinical Application APhA 2025: GLP-1 Receptor Agonists

This period is expected to be characterized by expansion of public reimbursement programs in major European and Asian markets, maturation of cardiovascular-anchored treatment protocols, and broader adoption across middle-income countries

A second paper, published in 1987, was a landmark: The tests showed that GLP-1 led to insulin secretion

doi: 10.2337/db17-1212

Mode of first delivery and postpartum weight retention at 1 year

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

9 Another case of exposure to dulaglutide during the first trimester of pregnancy for the treatment of type 2 diabetes did not result in any reported birth defects